Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Choosing a target for cognitive enhancers.

H Allain1, D Bentué-Ferrer, R Decombe

  • 1Laboratory of Experimental and Clinical Pharmacology, Pontchaillou Hospital and Medical School, Rennes, France.

Clinical Therapeutics
|July 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease.

European journal of neurology·2013
Same author

Assessment of interindividual variability of plasma concentrations after administrazion of high doses of intravenous amoxicillin or cloxacillin in critically ill patients.

Journal of chemotherapy (Florence, Italy)·2011
Same author

Evaluating patient satisfaction with specific migraine therapy based on initial treatment expectations: the PAX study.

Current medical research and opinion·2009
Same author

Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

General safety profile of zolpidem: safety in elderly, overdose and rebound effects.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same journal

Early Feasibility Studies in Europe: A Multisite Qualitative Study of Operational Challenges and Site Selection Determinants at 6 University Hospitals.

Clinical therapeutics·2026
Same journal

Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database.

Clinical therapeutics·2026
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
See all related articles

Developing drugs to enhance cognitive functions requires clearly defined targets. Identifying these pharmacologic targets will save time and resources, leading to more effective cognitive enhancers.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Cognitive enhancers aim to improve brain functions.
  • Drug development for cognitive enhancement faces challenges due to undefined targets.
  • Societal and medical needs drive the development of cognitive enhancers.

Purpose of the Study:

  • Outline justifications for developing cognitive enhancers.
  • Discuss procedures and therapeutic objectives for cognitive enhancer development.
  • Emphasize the importance of defining pharmacologic targets.

Main Methods:

  • Literature review on cognitive enhancer development.
  • Analysis of current challenges in the field.
  • Discussion of potential therapeutic strategies.

Related Experiment Videos

Main Results:

  • Failure to define pharmacologic targets hinders progress.
  • Clear targets are crucial for efficient drug development.
  • Developmental pathways and objectives were outlined.

Conclusions:

  • Defining direct pharmacologic targets is essential.
  • Target identification ensures cost and time savings.
  • Precisely defined targets lead to therapeutically effective agents.